SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-83482"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-83482" > Omega-3 fatty acid ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005706naa a2200505 4500
001oai:DiVA.org:uu-83482
003SwePub
008061103s2006 | |||||||||||000 ||eng|
009oai:DiVA.org:oru-74167
009oai:prod.swepub.kib.ki.se:1943575
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-834822 URI
0247 a https://doi.org/10.1001/archneur.63.10.14022 DOI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-741672 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:19435752 URI
040 a (SwePub)uud (SwePub)orud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Freund-Levi, Yvonne,d 1956-u Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden4 aut0 (Swepub:oru)yfi
2451 0a Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease :b OmegAD study - A randomized double-blind trial
264 1b American Medical Association (AMA),c 2006
338 a print2 rdacarrier
520 a Background: Epidemiologic and animal studies have suggested that dietary fish or fish oil rich in omega-3 fatty acids, for example, docosahexaenoic acid and eicosapentaenoic acid, may prevent Alzheimer disease (AD). Objective: To determine effects of dietary omega-3 fatty acid supplementation on cognitive functions in patients with mild to moderate AD. Design: Randomized, double-blind, placebo-controlled clinical trial. Participants: Two hundred four patients with AD (age range [mean +/- SD], 74 +/- 9 years) whose conditions were stable while receiving acetylcholine esterase inhibitor treatment and who had a Mini-Mental State Examination (MMSE) score of 15 points or more were randomized to daily intake of 1.7 g of docosahexaenoic acid and 0.6 g of eicosapentaenoic acid (omega-3 fatty acid-treated group) or placebo for 6 months, after which all received omega-3 fatty acid supplementation for 6 months more. Main Outcome Measures: The primary outcome was cognition measured with the MMSE and the cognitive portion of the Alzheimer Disease Assessment Scale. The secondary outcome was global function as assessed with the Clinical Dementia Rating Scale; safety and tolerability of omega-3 fatty acid supplementation; and blood pressure determinations. Results: One hundred seventy-four patients fulfilled the trial. At baseline, mean values for the Clinical Dementia Rating Scale, MMSE, and cognitive portion of the Alzheimer Disease Assessment Scale in the 2 randomized groups were similar. At 6 months, the decline in cognitive functions as assessed by the latter 2 scales did not differ between the groups. However, in a subgroup (n=32) with very mild cognitive dysfunction (MMSE > 27 points), a significant (P <.05) reduction in MMSE decline rate was observed in the omega-3 fatty acid-treated group compared with the placebo group. A similar arrest in decline rate was observed between 6 and 12 months in this placebo subgroup when receiving omega-3 fatty acid supplementation. The omega-3 fatty acid treatment was safe and well tolerated. Conclusions: Administration of omega-3 fatty acid in patients with mild to moderate AD did not delay the rate of cognitive decline according to the MMSE or the cognitive portion of the Alzheimer Disease Assessment Scale. However, positive effects were observed in a small group of patients with very mild AD (MMSE > 27 points).
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng
653 a MEDICINE
653 a MEDICIN
7001 a Eriksdotter-Jonhagen, Mariau Karolinska Institutet4 aut
7001 a Cederholm, Tommyu Karolinska Institutet,Uppsala universitet,Klinisk nutrition och metabolism,Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University Hospital, Uppsala, Sweden4 aut0 (Swepub:uu)tomce419
7001 a Basun, Hansu Uppsala universitet,Geriatrik,Division of Geriatrics, Uppsala University Hospital, Uppsala, Sweden4 aut0 (Swepub:uu)habas169
7001 a Faxén-Irving, Gerdu Karolinska Institutet4 aut
7001 a Garlind, Anitau Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden4 aut
7001 a Vedin, Ingeru Karolinska Institutet4 aut
7001 a Vessby, Bengtu Uppsala universitet,Klinisk nutrition och metabolism,Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University Hospital, Uppsala, Sweden4 aut0 (Swepub:uu)bengvess
7001 a Wahlund, Lars-Olofu Karolinska Institutet4 aut
7001 a Palmblad, Janu Karolinska Institutet4 aut
7102 a Karolinska Institutetb Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden4 org
7730 t Archives of Neurologyd : American Medical Association (AMA)g 63:10, s. 1402-1408q 63:10<1402-1408x 0003-9942x 1538-3687
8564 u https://jamanetwork.com/journals/jamaneurology/articlepdf/792554/noc60062.pdf
8564 u https://doi.org/10.1001/archneur.63.10.1402y Fulltext
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-83482
8564 8u https://doi.org/10.1001/archneur.63.10.1402
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-74167
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:1943575

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy